Related Experiment Video
Updated: Jul 19, 2026

Multilevel Oblique Lumbar Interbody Fusion in Degenerative Lumbar Disc Disease with Instability
Published on: July 25, 2025
The effect of infliximab, a monoclonal antibody against TNF-alpha, on disc herniation resorption: a randomized
Reijo A Autio1, Jaro Karppinen, Jaakko Niinimäki
1Department of Diagnostic Radiology, Oulu University Hospital, Oulu, Finland. reijo.autio@mhso.fi
Study Design:
Randomized, controlled study.
Objective:
To evaluate the effect of infliximab on herniated nucleus pulposus (HNP) resorption.
Summary Of Background Data:
Although the effects of tumor necrosis factor alpha (TNF-alpha) on HNP resorption are not fully understood, TNF-alpha appears to be an essential mediator in HNP resorption.
Methods:
As part of a substudy of the FIRST II study, magnetic resonance images (MRIs) were obtained from 21 patients who were candidates for discectomy at weeks 0, 2, 12, and 26 after receiving a single infusion of either 5 mg/kg infliximab (11 patients) or placebo (10 patients). The volume (mm3) of HNP, thickness (mm) and extent (%) of rim enhancement, and presence of nerve root edema were assessed.
Results:
HNP volume decreased significantly from baseline to 6 months in both treatment groups (P < 0.01), with no difference noted between the infliximab and placebo groups. By week 2, rim enhancement thickness increased significantly in the infliximab group compared with the placebo group (P = 0.003). Two patients in each group required back surgery before the 6-month assessment.
Conclusions:
Infliximab did not appear to interfere with disc herniation resorption over a 6-month period.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Degenerative Disc Disease ll: Pathophysiology
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids